CTOs on the Move

Headway Emotional Health Services

www.headway.org

 
Our psychiatrists, case workers, and medical and administrative staff are dedicated to helping people in emotional distress transform their lives through treatment, intervention and education. Headways services include outpatient therapy, DBT, psychia...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.headway.org
  • 6425, Nicollet Avenue
    Richfield, MN USA 55423
  • Phone: 612.861.1675

Executives

Name Title Contact Details

Similar Companies

EMSAR

You can depend on us. Our mission is to provide quality equipment services and repairs to our valued customers across the U.S. and Canada.

Cahaba Family Medicine

Cahaba Family Medicine Residency is an unopposed, community-based family medicine training program dually accredited by both the ACGME and AOA. Resurrection Family Medicine is now the Cahaba Urban Residency.

Consumer Healthcare Products Association

Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to promoting the increasingly vital role of OTC medicines and dietary supplements in America`s healthcare system through science, education, and advocacy.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.